Clinical Trial Update: Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV [Phase 3]

View source ↗

Summary

Phase 3 trial updating on nine-valent HPV vaccine to prevent persistent oral HPV infection in men living with HIV; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hpv Infection
• Hpv-positive Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Nine-valent HPV vaccine (HPV vaccine, nine-valent)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection | Phase 3 | Status: ACTIVE_NOT_RECRUITING